These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 1951289)
1. Re: "Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease". Thorogood M; Yudkin P Am J Epidemiol; 1991 Nov; 134(9):1009; author reply 1009-10. PubMed ID: 1951289 [No Abstract] [Full Text] [Related]
3. Oral contraception and the risk of thromboembolism: what does it mean to clinicians and their patients? Drife J Drug Saf; 2002; 25(13):893-902. PubMed ID: 12381211 [TBL] [Abstract][Full Text] [Related]
4. Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease. Gerstman BB; Piper JM; Tomita DK; Ferguson WJ; Stadel BV; Lundin FE Am J Epidemiol; 1991 Jan; 133(1):32-7. PubMed ID: 1983896 [TBL] [Abstract][Full Text] [Related]
5. Venous thromboembolism in women taking hormonal contraceptives. Blanco-Molina A; Monreal M Expert Rev Cardiovasc Ther; 2010 Feb; 8(2):211-5. PubMed ID: 20136607 [TBL] [Abstract][Full Text] [Related]
6. [Oral contraception and menopausal hormone replacement: effects on hemostasis and risk of venous thromboembolism]. Bounameaux H; de Moerloose P; Campana A Schweiz Med Wochenschr; 1996 Oct; 126(41):1756-63. PubMed ID: 8966508 [TBL] [Abstract][Full Text] [Related]
7. [Choice of the most suitable oral steroid contraceptive]. Presl J Cesk Gynekol; 1977 Aug; 42(7):523-5. PubMed ID: 890789 [No Abstract] [Full Text] [Related]
9. [Peroral hormonal contraception and risk of venous thromboembolism]. Ludka O; Spinar J; Musil V; Pozdísek Z Vnitr Lek; 2010 May; 56(5):370-5. PubMed ID: 20578585 [TBL] [Abstract][Full Text] [Related]
10. Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy: a clinical review. Gomes MP; Deitcher SR Arch Intern Med; 2004 Oct; 164(18):1965-76. PubMed ID: 15477430 [TBL] [Abstract][Full Text] [Related]
11. [Hormonal contraceptive therapy and thromboembolic disease]. Narvaiza MJ; Hernández M; Arrizabalaga B; Solana JM; Pérez Val JA; Rocha E Rev Med Univ Navarra; 1980 Dec; 24(4):49-53. PubMed ID: 7038816 [TBL] [Abstract][Full Text] [Related]
12. [Hormonal contraceptive agents as a risk factor in the development of acute thromboembolic diseases]. Lambrekht R; Vageman V; Vinkelman B; Geĭnrikh P Khirurgiia (Mosk); 1986 Dec; (12):90-3. PubMed ID: 3821001 [TBL] [Abstract][Full Text] [Related]
13. Hormonal contraception in women at risk of vascular and metabolic disorders: guidelines of the French Society of Endocrinology. Gourdy P; Bachelot A; Catteau-Jonard S; Chabbert-Buffet N; Christin-Maître S; Conard J; Fredenrich A; Gompel A; Lamiche-Lorenzini F; Moreau C; Plu-Bureau G; Vambergue A; Vergès B; Kerlan V Ann Endocrinol (Paris); 2012 Nov; 73(5):469-87. PubMed ID: 23078975 [TBL] [Abstract][Full Text] [Related]
14. Pharmacodynamics of combined estrogen-progestin oral contraceptives: 2. effects on hemostasis. Farris M; Bastianelli C; Rosato E; Brosens I; Benagiano G Expert Rev Clin Pharmacol; 2017 Oct; 10(10):1129-1144. PubMed ID: 28712325 [TBL] [Abstract][Full Text] [Related]